General description:
The pharmaceutical company Pepscan Systems B.V. is operational since 1999. Pepscan has 25 employees including 11 technicians, and 10 PhD’s.
The company has evolved from the Departement of Molecular Recognition of the Institute for Animal Science & Health in Lelystad. Pepscan’s activities are primarily focused on biomolecular interactions involving biologically important proteins as a lead to novel drugs, vaccines, and diagnostics.
Pepscan’s technology is based on more than 20 years of expertise in the mapping of protein-protein interactions by means of combinatorial synthesis (miniaturised parallel synthesis) of large peptide libraries. The company develops and exploits new screening methods with the ultimate objective to develop new drugs and synthetic vaccines.
Role in RUBICON:
Several sequence motifs for ubiquitin or SUMO-dependent destruction have been defined, but their precise structural aspects are often not yet understood. It will be essential to study the three-dimensional context of the degrons, as well as the specific SUMO-target sites to understand their specific roles, to identify them better and to provide a template for prediction in novel targets. For these studies good understanding of their target specificities is important.
In order to delineate the sumoylation site, we will synthesize and screen peptides with candidate sumoylation sites within different secondary structural setting (helix, sheet), different location within the secondary structure and different neighbouring residues to in order to describe the primary sequence motif and structural motif of the sumoylaiton site.
|
 |
|
Our Research
Research Projects
